VivoSeq
Other

Low Molecular Weight Heparin

0

Pipeline Programs↗

3

Active Trials↗

1

Companies Involved↗

Low Molecular Weight Heparin is an early-stage landscape with 0 programs across 1 company. The most active players are Rovi Pharmaceuticals Laboratories.

Intelligence

Pipeline Metrics

Competitive Density

14/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

88/100

Attrition Rate

8/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

R

Rovi Pharmaceuticals Laboratories

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

26

clinical trials

Completed15 · 58%
Unknown status6 · 23%
Terminated2 · 8%
Recruiting2 · 8%
Active, not recruiting1 · 4%

Clinical Trials

Trial Activity

26 trials

Anticoagulation Profile in Pregnant Women Treated With Three Times a Day of Low Molecular Weight Heparin (LMWH)
Recruiting·UUniversity of California, Irvine·Phase 4·NCT04861103·12 enrolled
THROmbinography in Pregnant Woman and in Vitro Action of Low Molecular Weight HEparin
Recruiting·UUniversity Hospital, Clermont-Ferrand·N/A·NCT06575309·50 enrolled
Low Molecular Weight Heparin vs Direct Oral Anticoagulant After Bariatric Surgery
Active, not recruiting·—·Phase 1·NCT06913595·100 enrolled
Intravenous Versus Subcutaneous Administration of Low Molecular Weight Heparin for Thromboprophylaxis in Critically Ill Patients
Completed·CClinique Saint Pierre Ottignies·Phase 4·NCT04982055·60 enrolled
Effect of Low Molecular Weight Heparin: Tinzaparin in Lung Tumours (TILT)
Completed·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT00475098·553 enrolled
Different Doses and Duration of Low Molecular Weight Heparin (Parnaparin)in Superficial Vein Thrombosis
Completed·IIRCCS Azienda Ospedaliero-Universitaria di Bologna·Phase 3·NCT00362947·664 enrolled
Low Molecular Weight Heparin for Hemodialysis Anticoagulation
Completed·TTehran University of Medical Sciences·N/A·NCT01356615·27 enrolled
Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of a New Ultra Low Molecular Weight Heparin (RO-14) Administered Subcutaneously Increasing Single-doses to Healthy Male Volunteers
Completed·RRovi Pharmaceuticals Laboratories·Phase 1·NCT00629733·12 enrolled
Comparison of 2 Low Molecular Weight Heparin as a Thromboprophylaxis Postpartum
Completed·HHawler Medical University·N/A·NCT01588171·7,020 enrolled
Low Molecular Weight Heparin in Pregnancies With Unexplained Stillbirths
Completed·HHawler Medical University·Phase 1·NCT03601338·140 enrolled
ABRIDGE: Low Molecular Weight Heparin in Bridging Patients After Mechanical Valve Replacement
Completed·TThe Cleveland Clinic·Phase 4·NCT00298285·100 enrolled
Efficacy of Low Molecular Weight Heparin in Superficial Vein Thrombosis
Completed·UUniversity Medical Centre Ljubljana·Phase 4·NCT01245998·68 enrolled
Low Molecular Weight Heparin in Recurrent Implantation Failure
Completed·VV.K.V. American Hospital, Istanbul·N/A·NCT00750451
Low Molecular Weight Heparin vs Unfractionated Heparin at Cardiac Surgery
Completed·GG. d'Annunzio University·N/A·NCT00420667·43 enrolled
Local Uterine Application of Low Molecular Weight Heparin (LMWH) in Intra-cytoplasmic Sperm Injection (ICSI)
Completed·TThe Egyptian IVF-ET Center·Phase 1·NCT02325479·120 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)